Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: June 2014


Related content

Powered by UNSILO

Suggested reading

French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA. Adjunctive perampanel for refractory partial-onset seizures. Randomized phase III study 304. Neurology 2011; 79: 589–596.
Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatekeyama S, Ohgoh M, Ueno M, Nishizawa Y. Perampanel: A novel, orally active, noncompetitive AMPA-receptotr antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011; 52: 1331–1340.
Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D. Tolerability and safety of perampanel: two randomizerd dose-escalation studies. Acta Neurologica Scandinavica 2012; 125: 8–15.
Krauss GL, Serratosa JM, Villanueva V, Endziniene E, Hong Z, French J, Yang H, Squillacote D, Edwards HB, Zhu J, Laurenza A. Randomized phase III study 306. Adjunctive perampanel for refractory partial-onset seizures. Neurology 2012; 78: 1408–1415.
Ledingham DRM, Patsalos PN. Perampanel: What is its place in the management of partial epilepsy? Neurology and Therapy 2013; in press.
Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs) – Part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clinical Pharmacokinetics 2013; DOI 10.1007/S40262-013-0087-0.